Determining the presence of a protein in non-tumor cells within the cancer microenvironment could be one of the keys to establishing prognosis in patients with colon and rectal cancer. It may also help identify which patients could benefit from immunotherapy or from treatments aimed at inhibiting a specific protein linked to tumor proliferation.
This article was originally published on MedicalXpress.com

